Current treatment options for patients with initially unresectable isolated colorectal liver metastases.

about

Current treatment options for patients with initially unresectable isolated colorectal liver metastases.

Item

http://www.wikidata.org/entity/Q42540076

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current treatment options for ...... d colorectal liver metastases.

@en

Current treatment options for ...... d colorectal liver metastases.

@nl

type

Item

label

Current treatment options for ...... d colorectal liver metastases.

@en

Current treatment options for ...... d colorectal liver metastases.

@nl

prefLabel

Current treatment options for ...... d colorectal liver metastases.

@en

Current treatment options for ...... d colorectal liver metastases.

@nl

P1476

Current treatment options for ...... d colorectal liver metastases.

@en

P2093

Ozkan Kanat

http://www.w3.org/2001/XMLSchema#string

P2860

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.

P304

9-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.5306/WJCO.V7.I1.9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292386821

http://www.w3.org/2001/XMLSchema#string

P698

26862487

http://www.w3.org/2001/XMLSchema#string

P932

4734940

http://www.w3.org/2001/XMLSchema#string